ESR1 and breast cancer: AZD8835 is an isoform-selective inhibitor of PI3Kα and PI3Kδ that preferentially inhibits cells growth with mutant PIK3CA status such as in estrogen receptor-positive (ER+) breast cancer cell lines and xenografts (Hudson et al., 2016).